Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2025-10-22 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing that a company executive will participate in an upcoming investor conference (Truist Securities Biopharma Symposium). It provides details about the event, the speaker, and the company's background, but it does not contain the actual presentation slides or a transcript of the event. Since it is a general regulatory announcement regarding corporate activities that does not fit into specific categories like earnings releases or reports, it is classified as a general regulatory filing.
2025-10-22 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Teva Pharmaceuticals announcing the FDA approval of an expanded indication for their drug, UZEDY. It follows the standard structure of a corporate press release, including a headline, dateline, quotes from executives, background information on the product, and a cautionary note regarding forward-looking statements. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement, it is classified as a general regulatory filing/announcement.
2025-10-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release issued by Medincell and Teva Pharmaceuticals announcing the FDA approval of an expanded indication for their drug UZEDY. It details the clinical context, the nature of the approval, and provides contact information for investor relations. As it is a corporate announcement regarding a specific regulatory milestone (FDA approval) rather than a full financial report or a simple report publication notice, it falls under the category of general regulatory announcements or corporate news.
2025-10-10 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 95% confidence The document is a standard regulatory disclosure required by the AMF (Autorité des Marchés Financiers) under Article 223-16, detailing the total number of shares and voting rights for MedinCell. This type of filing is a routine regulatory update regarding capital structure and does not fit into specific categories like M&A, dividends, or earnings releases. Therefore, it is classified as a general regulatory filing.
2025-10-10 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release issued by Medincell announcing the regulatory approval of their product LONGAVO in Canada. It follows the standard format of a corporate press release, providing details on the product, the partnership with Teva, and company background. It does not constitute a formal financial report, audit, or proxy statement, but rather a general regulatory and corporate announcement. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-09-23 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing the regulatory approval of a drug (LONGAVO) by Health Canada. It provides details about the company's product pipeline and technology but does not constitute a formal financial report, audit, or shareholder meeting material. As it is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific categories like M&A or earnings releases, it is classified as a Regulatory Filing (RNS).
2025-09-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.